ReviewArthritis research & therapy2011
Cytokine disturbances in systemic lupus erythematosus.
Review in Arthritis research & therapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 1 synthesis or guideline pooled it, 144 citations in OpenAlex.
- Efficacy and safety study of targeted small-molecule drugs in the treatment of systemic lupus erythematosus.Arthritis research & therapy · 2024Pooled it
- The landscape of cellular immune alteration in systemic lupus erythematosus.Frontiers in immunology · 2026Review
- Interleukin 16 in lupus nephritis-a role for Th1 and CD8+ T cell migration.Clinical and experimental immunology · 2025Article
- Immunotargets and Therapy for Systemic Lupus Erythematosus.ImmunoTargets and therapy · 2025Review
- Immune metabolic restoration in systemic lupus erythematosus: the impact of gut microbiota, probiotics, and nutritional synergy.Frontiers in immunology · 2025Review
- Melatonin, an Antitumor Necrosis Factor Therapy.Journal of pineal research · 2025Review
- Cytokines unveiled: their impact on oral and multisystem features of lupus erythematosus.Frontiers in immunology · 2025Review
- The Impact of the IL-10 Gene Polymorphism on mRNA Expression and IL-10 Serum Concentration in Polish Lupus Patients.International journal of molecular sciences · 2024Article
- The effects of Lactobacillus delbrueckii and Lactobacillus rhamnosus on cytokines and their related molecules: AnArchives of rheumatology · 2023Article
- SHP2: its association and roles in systemic lupus erythematosus.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2023Article
- Article
- Involvement of Gut Microbiota in SLE and Lupus Nephritis.Biomedicines · 2023Review
- Serum cytokines to predict systemic lupus erythematosus clinical and serological activity.Clinical and translational science · 2022Article
- Phenotypic and functional alterations of peritoneal macrophages in lupus-prone mice.Molecular biology reports · 2022Article
- Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: Biological role in induction, regulation, and treatment.Frontiers in immunology · 2022Review
- COVID-19 vaccination followed by activation of glomerular diseases: does association equal causation?Kidney international · 2021Article
- Sialoglyco-Conjugate Abnormalities, IL-6 Trans-Signaling and Anti-Ganglioside Immune Response-Potential Interferences in Lupus Nephritis Pathogenesis.Diagnostics (Basel, Switzerland) · 2021Article
- Article
- Salivary Cytokines as Potential Diagnostic Biomarkers for Systemic Lupus Erythematosus Disease.Mediators of inflammation · 2021Review
- The role of endocan and selected pro-inflammatory cytokines in systemic lupus erythematosus.Postepy dermatologii i alergologii · 2020Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The pathogenesis of systemic lupus erythematosus (SLE) is complex, and the resulting disease manifestations are heterogeneous. Cytokine dysregulation is pervasive, and their protein and gene expression profiles may serve as markers of disease activity and severity. Importantly, biologic agents that target specific cytokines may represent novel therapies for SLE. Four cytokines (IL-6, TNFα, IFNα, and BLyS) are being evaluated as therapeutic targets in SLE. The present review will examine the roles of each of these cytokines in murine and human SLE, and will summarize results from clinical trials of agents that target these cytokines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.